Protalix BioTherapeutics Logo
US74365A3095
A2PWSL
PLX

Protalix BioTherapeutics

Previsión

El precio objetivo medio de los analistas es de 5,47 € (+107,98 %). La mediana es de 5,47 € (+107,98 %).

Comprar
  5
Mantener
  2
Vender
  0

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • Protalix reports strong revenue and profit growth in Q2 2026, stock slightly lower premarket

    Protalix increased revenue in the second quarter to $19.9 million (+26.8%) and reported a net profit of $3.8 million (EPS $0.05). Product sales were driven primarily by Elfabrio to Chiesi; the company holds $40.7 million in cash and is debt-free. Management reaffirmed the 2026 revenue guidance but noted variable ordering patterns from partners and a pipeline that is still maturing; top-line data for PRX-115 are expected in H2 2027. The stock fell modestly by 0.41% in premarket trading. » Más en de.investing.com


  • Protalix beats revenue expectations but misses EPS and shares plunge

    Protalix reported Q4 2025 revenue of $52.74 million versus expected $18.35 million, but missed on earnings per share at -$0.08 (forecast $0.035). The stock fell about 13% in premarket trading after the company reported a net profit swing to a $6.6 million loss for the fiscal year. Higher R&D costs (+51% to $19.6 million) and increased cost of sales weighed on profitability, while sales to Pfizer supported the strong revenue. Protalix expects a $25 million milestone payment and sees opportunities from a potential European approval of a new Elfabrio dosing regimen. » Más en de.investing.com


  • Protalix partners with Secarna to develop antisense therapies for rare kidney diseases

    Protalix and Secarna have entered a collaboration and option agreement to develop antisense oligonucleotide therapies for rare kidney diseases. Protalix will identify pharmaceutical targets, Secarna will use its AI platform OligoCreator to design candidate molecules, and Protalix will receive an exclusive license option for clinical development and commercialization. The agreement marks Protalix’s first expansion into rare kidney diseases using RNA technologies; financial terms were not disclosed. Protalix also reported a Q3 2025 EPS and revenue miss versus analyst expectations. » Más en de.investing.com


  • Protalix misses Q3 2025 earnings forecast, stock falls sharply premarket

    Protalix reported Q3 2025 earnings per share of $0.03, missing the $0.07 expectation; quarterly revenue was $17.67 million versus an estimated $17.79 million. The stock fell 13.55% in premarket trading to $1.85. For the first nine months, the company reported revenue growth of 24% to $43.6 million and held $29.4 million in cash; Protalix plans to start a phase 2 study for PRX-115 before year-end with initial results expected in Q3 2027. » Más en de.investing.com


  • Protalix and Chiesi seek re-evaluation of negative EMA opinion on Elfabrio

    Protalix and Chiesi Global Rare Diseases have requested a re-evaluation of the EMA’s negative opinion on the proposed alternative dosing regimen for Elfabrio. The aim is to approve an additional option of 2 mg/kg every four weeks alongside the existing 1 mg/kg every two weeks for the treatment of adult patients with Fabry disease. The current marketing authorization remains in effect during the procedure; the final decision will be made by the European Commission after the review is completed. Elfabrio carries a warning for hypersensitivity reactions; Protalix will publish quarterly results on November 17. » Más en de.investing.com

Datos financieros

En el último trimestre, Protalix BioTherapeutics tuvo unos ingresos de 19,36 M € y un beneficio neto de 3,5 M €

(EUR) septiembre de 2026
YoY
Ingresos 19,36 M 27,25 %
Beneficio bruto 12,4 M 52,78 %
Beneficio neto 3,5 M 74,26 %
EBITDA 4,47 M 88,09 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
232,07 M €
Número de acciones
84,32 M
Máximo/mínimo de 52 semanas
2,91 € - 1,50 €
Dividendos No
Beta
0,01
Ratio P/E
11,61
Ratio PEG
-0,02
Ratio P/B
3,02
Ratio P/S
3,01

Perfil de la empresa

Protalix BioTherapeutics, Inc., una empresa biofarmacéutica, se centra en el desarrollo y la comercialización de proteínas terapéuticas recombinantes basadas en su sistema patentado de expresión de proteínas ProCellEx, a partir de células vegetales, en Estados Unidos, Australia, Canadá, Israel, Brasil, Rusia, Turquía e internacionalmente. La compañía ofrece Elelyso para el tratamiento de la enfermedad de Gaucher. Su cartera de productos comprende PRX-102, una proteína terapéutica candidata, que se encuentra en la última fase de los ensayos clínicos para el tratamiento de la enfermedad de Fabry; PRX-110, una forma recombinante patentada de la desoxirribonucleasa I humana expresada en células vegetales, que ha completado los ensayos clínicos de fase IIa para el tratamiento de la fibrosis quística; PRX-115, una uricasa recombinante PEGilada expresada en células vegetales para el tratamiento de la gota; y PRX-119, un producto candidato de ADNasa I humana recombinante PEGilada expresada en células vegetales para el tratamiento de enfermedades relacionadas con NETs. La compañía tiene acuerdos y alianzas con Pfizer; la Fundação Oswaldo Cruz (Fiocruz); y Chiesi Farmaceutici S.p.A. La empresa fue fundada en 1993 y tiene su sede en Hackensack, Nueva Jersey.

Nombre
Protalix BioTherapeutics
CEO
Dror Bashan
Sede Hackensack, nj
Israel
Sitio web
Sector
Consumo básico
Industria
Productos alimenticios
Salida a bolsa
15/05/1998
Empleados 226

Símbolos bursátiles

Bolsa Símbolo
AMEX
PLX
Frankfurt
PBDA.F
Düsseldorf
PBDA.DU
München
PBDA.MU
🍪

Parqet  usa cookies. Más información